Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Tirzepatide for Sale > Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales
Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales buy - large image1
Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales buy - image1
Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales buy - image2
Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales buy - image3
Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales buy - image4
Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales buy - image5
Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales buy - image6

Tirzepatide CAS:2023788-19-2 2023788-19-2 Purity 99% on sales

2098 Inquiries

Unit Price: Get Latest Price
CAS No.:

2023788-19-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

ningbo

Brand:

maxshow

Packaging:

5mg 10mg 15mg 30mg per vial; 10vials/box

Sample Available:

Yes

Price valid (until):

2026-01-10

Company Type:
Trader
Location:
The British Virgin Islands
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
7 days
Qualification:
Main Products:

peptides

  • Product Details

  • Seller Information

  • Inquiry History

  • Description

    Shop wholesale price TD from China  CAS 5721-91-5-Detailed Image 1 Shop wholesale price TD from China  CAS 5721-91-5-Detailed Image 2 Shop wholesale price TD from China  CAS 5721-91-5-Detailed Image 3 Shop wholesale price TD from China  CAS 5721-91-5-Detailed Image 4 Shop wholesale price TD from China  CAS 5721-91-5-Detailed Image 5 Shop wholesale price TD from China  CAS 5721-91-5-Detailed Image 6


    Quick Guide:

    1. Mass production customize available.

    2. Cap color customize, please ask our sales rep. for more color plans.

    3. Vial size and mg content size customize

    4. Shipping channels secure.

    5. Vaccum seal for all of vials. 

    6. Fresh batch every 6-8 days. 

    Appearance: Powder

    Purity: >98% (or refer to the Certificate of Analysis)

    Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

    Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

    Solubility: To be determined

    Shelf Life: >2 years if stored properly

    Drug Formulation: To be determined

    Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

    Product Name

    sem

    Appea rance

    White powder

    Specification

    2mg,5mg,10mg,20mg,30mg,1g,5g(Customizable)

    Packing

    Bottle,Box,Cartons

    MOQ

    10 Box (100 vials)

    Purity

    99% Above

    Function

    Weight Loss

    Storage

    Refrigerate and seal at 2-8℃

    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    peptides

    Location:

    BRITISH VIRGIN ISLANDS

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7 days

    Total Annual Revenue:

    $2.5 million-$5 million

    Total Employees:

    11-50

    Year of Establishment:

    2024

  • Inquiry History
    2098 Inquiries
    Country Product Purchase Quantity Date Posted
    Philippines

    Tirzepatide

    30 MG Oct 26, 2026
    Slovakia

    Tirzepatide

    1 G Oct 26, 2026
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    5 MT Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    United States

    Tirzepatide

    10 MT Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    United States

    Tirzepatide

    50 MG Oct 20, 2026
    Spain

    tirzepatide

    20 MG Oct 19, 2026
    United States

    tirzepatide

    30 MG Oct 19, 2026
    Philippines

    tirzepatide

    40 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    Tirzepatide

    20 MG Oct 19, 2026
    United States

    Tirzepatide

    300 MG Oct 19, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.